PRV111 (Cisplatin Transmucosal System)

DRUG2 trials

Sponsors

Privo Technologies

Conditions

Oral Squamous Cell Carcinoma

Phase 1

Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

CompletedNCT03502148

Privo TechnologiesOral Squamous Cell Carcinoma

Start: 2018-06-19End: 2020-05-06Updated: 2022-10-21

Phase 2

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

RecruitingNCT05893888

Privo TechnologiesOral Squamous Cell Carcinoma

Start: 2024-11-07End: 2027-05-31Target: 40Updated: 2026-04-23

Related Papers

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer.

2022-08-1738 citations

A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC).

Journal of Clinical Oncology2021-05-205 citations